Details for Patent: 9,649,311
Which drugs does patent 9,649,311 protect, and when does it expire?
Patent 9,649,311 protects ISENTRESS HD and is included in one NDA.
Protection for ISENTRESS HD has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has thirty-three patent family members in twenty-six countries.
Summary for Patent: 9,649,311
| Title: | Solid pharmaceutical compositions containing an integrase inhibitor |
| Abstract: | Compressed tablets for oral administration containing raltegravir in the form of a pharmaceutically acceptable salt are described. The tablets comprise: (A) an intragranular component comprising (i) an effective amount of an alkali metal salt of raltegravir, (ii) optionally a first superdisintegrant, and (iii) a binder; and (B) an extragranular component comprising (i) a second superdisintegrant, (ii) a filler, and (iii) a lubricant. Methods for preparing the tablets and the use of the tablets, optionally in combination with other anti-HIV agents, for the inhibition of HIV integrase, for the treatment or prophylaxis of HIV infection, or for the treatment, delay in the onset, or prophylaxis of AIDS are also described. |
| Inventor(s): | Majid Mahjour, Feng Li, Decheng MA, Sutthilug Sotthivirat |
| Assignee: | Merck Sharp and Dohme LLC |
| Application Number: | US13/503,939 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,649,311 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Process; Dosage form; |
Drugs Protected by US Patent 9,649,311
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Msd Sub Merck | ISENTRESS HD | raltegravir potassium | TABLET;ORAL | 022145-002 | May 26, 2017 | AB | RX | Yes | Yes | 9,649,311*PED | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,649,311
| PCT Information | |||
| PCT Filed | October 21, 2010 | PCT Application Number: | PCT/US2010/053507 |
| PCT Publication Date: | May 05, 2011 | PCT Publication Number: | WO2011/053504 |
International Family Members for US Patent 9,649,311
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2010313571 | ⤷ Start Trial | |||
| Brazil | 112012009857 | ⤷ Start Trial | |||
| Canada | 2777937 | ⤷ Start Trial | |||
| China | 102655752 | ⤷ Start Trial | |||
| China | 106074411 | ⤷ Start Trial | |||
| Colombia | 6531485 | ⤷ Start Trial | |||
| Cyprus | 1124914 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
